APP Pharmaceuticals receives FDA approval to advertise Ganciclovir for Injection, USP APP Pharmaceuticals, Inc., a wholly possessed subsidiary of Fresenius Kabi Pharmaceuticals Keeping, Inc., announced today that it provides received authorization from the U.S. Food and Drug Administration to market Ganciclovir for Injection, USP. APP’s Ganciclovir for Injection is certainly AP-rated, bar-coded and latex-free. According to IMS Wellness, sales of this product for 2009 in the usa were approximately $13.5 million. Ganciclovir for Injection can be an antiviral drug, which is used in the treating Cytomegalovirus retinitis in immunocompromised patients, including sufferers with acquired immunodeficiency syndrome , as well as for the prevention of CMV disease in transplant recipients at risk for CMV disease.These data will end up being presented at the 2010 American College of Rheumatology Annual Scientific Interacting with in Atlanta, 7-11 November, 2010. Data shown at ACR provide further proof the long-term benefits of Actemra in reducing the signs or symptoms in patients with moderate to serious RA, said Hal Barron, M.D., executive vice president, Product Advancement and chief medical officer. Also, we have become excited about the new data that showed that Actemra helped kids who were experiencing sJIA, the most severe form of juvenile arthritis. Data from the Phase III TENDER study showed 85 % of children with systemic Juvenile Idiopathic Arthritis receiving ACTEMRA experienced a 30 % improvement in the signs and symptoms of sJIA and an lack of fever after 90 days of therapy, compared with 24 % of kids receiving placebo .